(Q51054919)

27 March 2018

meta-analysis

0 references

title

Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. (English)

1 reference

27 March 2018

0 references

0 references

1

1 reference

27 March 2018

author name string

Li-Na Tang

2

1 reference

27 March 2018

Ai-Na He

3

1 reference

27 March 2018

Yang Yao

4

1 reference

27 March 2018

Zan Shen

5

1 reference

27 March 2018

publication date

20 April 2013

1 reference

27 March 2018

International Journal of Clinical Oncology

published in

1 reference

27 March 2018

volume

19

1 reference

27 March 2018

issue

2

1 reference

27 March 2018

page(s)

403-410

1 reference

27 March 2018

https://scigraph.springernature.com/pub.10.1007/s10147-013-0561-6

exact match

0 references

cites work

Operating characteristics of a rank correlation test for publication bias

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Effects of bone-targeted agents on cancer progression and mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Relevance of a prolonged preoperative antibiotic regime in the treatment of bisphosphonate-related osteonecrosis of the jaw.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Management of bone metastases in refractory prostate cancer--role of denosumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Osteonecrosis of the jaw and the role of macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Prostate cancer: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Jaw osteonecrosis in patients treated with bisphosphonates: an ultrastructural study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Bisphosphonate-related osteonecrosis of jaw (BRONJ): an anti-angiogenic side-effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Osteonecrosis of jaw associated with bisphosphonate use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Bisphosphonates and osteonecrosis of the jaw.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Bisphosphonate induced osteonecrosis of jaw in breast cancer patients: A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Antiresorptives and osteonecrosis of the jaw.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0561-6

Skeletal complications of malignancy

21 January 2018

1 reference

12 December 2020

American Association of Oral and Maxillofacial Surgeons position paper: Bisphosphonate-Related Osteonecrosis of the Jaws-2009 update: the need to refine the BRONJ definition

1 reference

12 December 2020

Heterogeneity testing in meta-analysis of genome searches

1 reference

12 December 2020

Bisphosphonate-induced osteonecrosis of the jaw

1 reference

12 December 2020

1 reference

12 December 2020

Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws

1 reference

12 December 2020

Rank/Rankl/opg: literature review

1 reference

12 December 2020

Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients

1 reference

12 December 2020

Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases

1 reference

12 December 2020

1 reference

12 December 2020

Epidemiology and pathogenesis of osteonecrosis of the jaw.

1 reference

12 December 2020

10.1007/S10147-013-0561-6

Identifiers

DOI

1 reference

27 March 2018

PubMed ID

23605142

1 reference

27 March 2018